Manasa

Acetylsalicylic Acid and Rosuvastatin, the active ingredients in Manasa, are an antiplatelet agent and an HMG‑CoA reductase inhibitor presented as oral tablets for cardiovascular disease prevention. They are used to lower cholesterol and reduce platelet aggregation, helping to prevent heart attacks, strokes, and related vascular events in adults at risk.

GNH USA supplies Manasa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manasa combines an antiplatelet and a statin to address cardiovascular risk factors and lipid disorders.

Primary prevention of cardiovascular events: lowers the incidence of heart attack and stroke in patients without prior events. Secondary prevention of cardiovascular events: reduces recurrence of myocardial infarction or ischemic stroke after an initial event. Hyperlipidemia: decreases LDL‑cholesterol and total cholesterol levels. Atherosclerotic cardiovascular disease: slows plaque progression and improves arterial health.

Manasa may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia. - Mild headache. - Transient elevation of liver enzymes. - Muscle aches or weakness. - Minor bruising or bleeding at sites of injury.

Serious or Rare Side Effects: - Severe gastrointestinal bleeding or ulceration. - Rhabdomyolysis with muscle breakdown and renal impairment. - Anaphylactic or severe hypersensitivity reactions.

Before prescribing Manasa, clinicians should assess patient history and monitor relevant parameters. - Renal or hepatic impairment: adjust monitoring and consider alternative therapy. - History of peptic ulcer disease or bleeding: evaluate risk versus benefit. - Concomitant use of other anticoagulants or antiplatelet agents: increase bleeding surveillance. - Pregnancy or breastfeeding: use only if clearly needed after risk assessment. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Manasa can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other antiplatelet or anticoagulant agents (e.g., clopidogrel, warfarin): heightened bleeding risk. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase rosuvastatin exposure.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive gastrointestinal irritation. - Fibrates (e.g., gemfibrozil): increased risk of myopathy. - ACE inhibitors or ARBs: potential for reduced antihypertensive effect. - Digoxin: possible increase in serum concentrations.